Tempus AI, Inc.
TEM
Rank in Stocks
#1886
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Share Price
$64.29
Last synced: 2026-10-16
Market Cap
$11.28B
Change (1 day)
-9.62%
Change (1 year)
-26.76%
Country
US
Trade Tempus AI, Inc. (TEM)
Category
Healthcare
Operating Margin for Tempus AI, Inc. (TEM)
Operating Margin as of October 2026 TTM: -19.76%
According to Tempus AI, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -19.76%. At the end of 2023 the company had an Operating Margin of -36.87%.
Operating Margin history for Tempus AI, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -19.76% | -80.17% |
| 2024 | -99.67% | 170.33% |
| 2023 | -36.87% | -55.46% |
| 2022 | -82.78% | -12.42% |
| 2021 | -94.52% | -8.14% |
| 2020 | -102.90% | -46.69% |
| 2019 | -193.02% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 12.70% | -100.64% |
US
|
|
| 74.94% | -103.79% |
AU
|
|
| 3.33% | -100.17% |
US
|
|
| -14.33% | -99.27% |
US
|
|
| 0.00% | - |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.